Walter Knight

Walter joined Bayer as an associate principal scientist in September 2025 and is a visiting scientist at the PCL at Broad.

Prior to joining Bayer, he worked at Bristol Myers Squibb and Inscripta in the San Francisco Bay Area. Knight brings a strong background in cardiovascular drug discovery and screening as well as cell-based models of cardiovascular disease, with a focus on stem cell derived cardiomyocytes.

Prior to moving to industry, Knight contributed to the development of iPSC-based models of hypertrophic cardiomyopathy as well as cardiac maturation platforms in the laboratory of Dr. Kunhua Song at the University of Colorado, and characterized the roles of phosphodiesterase 1C in systolic heart failure in the laboratory of Dr. Chen Yan at the University of Rochester.

Knight earned his Ph.D. in molecular pharmacology from the University of Rochester.